The U.S. emerged as a major region for the ADHD market due to increased healthcare expenditure incurred on the treatment & diagnosis of the ADHD patients and growth in the number of hospitals & clinics offering EEG biofeedback & dual therapy. The global attention deficit hyperactivity disorder (ADHD) market is expected to grow with increasing pharmaceutical R&D spending, growing healthcare expenditure, accelerating economic growth, unmet treatment needs and mounting occurrence of ADHD.